[go: up one dir, main page]

FI924574A0 - Genterapi foer cellproliferativa sjukdomar - Google Patents

Genterapi foer cellproliferativa sjukdomar

Info

Publication number
FI924574A0
FI924574A0 FI924574A FI924574A FI924574A0 FI 924574 A0 FI924574 A0 FI 924574A0 FI 924574 A FI924574 A FI 924574A FI 924574 A FI924574 A FI 924574A FI 924574 A0 FI924574 A0 FI 924574A0
Authority
FI
Finland
Prior art keywords
genterapi
cellproliferativa
sjukdomar
foer
dna
Prior art date
Application number
FI924574A
Other languages
English (en)
Other versions
FI924574A7 (fi
FI924574L (fi
Inventor
Yuen K Fung
Alan L Murphree
Original Assignee
Res Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Dev Foundation filed Critical Res Dev Foundation
Publication of FI924574A0 publication Critical patent/FI924574A0/fi
Publication of FI924574A7 publication Critical patent/FI924574A7/fi
Publication of FI924574L publication Critical patent/FI924574L/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI924574A 1990-04-10 1991-04-10 Genterapi foer cellproliferativa sjukdomar FI924574L (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50741790A 1990-04-10 1990-04-10
PCT/US1991/002478 WO1991015580A1 (en) 1990-04-10 1991-04-10 Gene therapy for cell proliferative diseases

Publications (3)

Publication Number Publication Date
FI924574A0 true FI924574A0 (fi) 1992-10-09
FI924574A7 FI924574A7 (fi) 1992-10-09
FI924574L FI924574L (fi) 1992-10-09

Family

ID=24018569

Family Applications (1)

Application Number Title Priority Date Filing Date
FI924574A FI924574L (fi) 1990-04-10 1991-04-10 Genterapi foer cellproliferativa sjukdomar

Country Status (18)

Country Link
EP (2) EP0960941A1 (fi)
JP (1) JPH05507067A (fi)
KR (1) KR100304033B1 (fi)
CN (1) CN1057121C (fi)
AT (1) ATE190652T1 (fi)
AU (3) AU7750191A (fi)
CA (1) CA2079903A1 (fi)
DE (1) DE69132047T2 (fi)
DK (1) DK0527804T3 (fi)
ES (1) ES2143463T3 (fi)
FI (1) FI924574L (fi)
GR (1) GR3033695T3 (fi)
IE (2) IE20010427A1 (fi)
IL (1) IL97774A0 (fi)
NO (1) NO923917L (fi)
PT (1) PT97316B (fi)
WO (1) WO1991015580A1 (fi)
ZA (1) ZA912491B (fi)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7384735B1 (en) 1986-08-11 2008-06-10 Massachusetts Eye And Ear Infirmary Retinoblastoma nucleic acids
US7223842B1 (en) 1986-08-11 2007-05-29 Massachusetts Eye And Ear Infirmary Detection of proteins whose absence is associated with a neoplasm
US5532220A (en) * 1987-08-31 1996-07-02 The Regents Of The University Of California Genetic mechanisms of tumor suppression
NO312681B1 (no) * 1990-08-24 2002-06-17 Univ California Fremgangsmåte for fremstilling av en farmasöytisk blanding med suppresiv virkning/aktivitet
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
AU663702B2 (en) 1991-03-06 1995-10-19 Board Of Regents, The University Of Texas System Methods and compositions for the selective inhibition of gene expression
US5262321A (en) * 1991-05-31 1993-11-16 Dana-Farber Cancer Institute DNA encoding p107 tumor suppressor
JP4111463B2 (ja) * 1991-08-23 2008-07-02 ボード・オブ・リージェンツ・オブ・ジ・ユニバーシティ・オブ・ネブラスカ 細胞リプログラミング方法及び組成物
US6348327B1 (en) 1991-12-06 2002-02-19 Genentech, Inc. Non-endocrine animal host cells capable of expressing variant proinsulin and processing the same to form active, mature insulin and methods of culturing such cells
US5302706A (en) * 1991-12-16 1994-04-12 Baylor College Of Medicine Senescent cell derived inhibitors of DNA synthesis
US6420172B1 (en) * 1992-04-20 2002-07-16 Tib Company, Llc Method for inducing tumor immunity
US5496698A (en) * 1992-08-26 1996-03-05 Ribozyme Pharmaceuticals, Inc. Method of isolating ribozyme targets
AU687736B2 (en) * 1992-05-11 1998-03-05 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting viral replication
US5610054A (en) * 1992-05-14 1997-03-11 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecule targeted against Hepatitis C virus
US6258585B1 (en) 1992-05-14 2001-07-10 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting influenza virus replication
US5972699A (en) 1992-05-14 1999-10-26 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting herpes simplex virus replication
US5750390A (en) * 1992-08-26 1998-05-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of diseases caused by expression of the bcl-2 gene
US5610052A (en) * 1992-08-26 1997-03-11 Ribozyme Pharmaceuticals Inc. Enzymatic RNA with activity to ras
US5622854A (en) * 1992-05-14 1997-04-22 Ribozyme Pharmaceuticals Inc. Method and reagent for inhibiting T-cell leukemia virus replication
US6492512B1 (en) 1992-08-26 2002-12-10 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of lung cancer and other malignancies caused by the deregulation of L-MYC gene expression
US5693535A (en) * 1992-05-14 1997-12-02 Ribozyme Pharmaceuticals, Inc. HIV targeted ribozymes
US5989906A (en) * 1992-05-14 1999-11-23 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting P-glycoprotein (mdr-1-gene)
US5525468A (en) * 1992-05-14 1996-06-11 Ribozyme Pharmaceuticals, Inc. Assay for Ribozyme target site
JPH07509133A (ja) * 1992-07-17 1995-10-12 リボザイム・ファーマシューティカルズ・インコーポレイテッド 動物疾患の処置のための方法および剤
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
US6544755B1 (en) 1992-08-26 2003-04-08 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of diseases by expression of the c-Myc gene
US5599704A (en) * 1992-08-26 1997-02-04 Ribozyme Pharmaceuticals, Inc. ErbB2/neu targeted ribozymes
WO1994006910A1 (en) * 1992-09-18 1994-03-31 Canji, Inc. Gene therapy by retroviral vector with tumor suppressive gene
JPH08501686A (ja) 1992-09-25 1996-02-27 ローン−プーラン・ロレ・ソシエテ・アノニム 中枢神経系、特に脳における細胞への外来遺伝子の転移のためのアデノウィルスベクター
JPH08506008A (ja) 1992-11-18 1996-07-02 アーチ ディベロプメント コーポレイション 心筋及び血管平滑筋へのアデノウィルス介在遺伝子移入
US5616490A (en) * 1992-12-07 1997-04-01 Ribozyme Pharmaceuticals, Inc. Ribozymes targeted to TNF-α RNA
US5612215A (en) * 1992-12-07 1997-03-18 Ribozyme Pharmaceuticals, Inc. Stromelysin targeted ribozymes
US5837542A (en) 1992-12-07 1998-11-17 Ribozyme Pharmaceuticals, Inc. Intercellular adhesion molecule-1 (ICAM-1) ribozymes
US5658780A (en) 1992-12-07 1997-08-19 Ribozyme Pharmaceuticals, Inc. Rel a targeted ribozymes
US5811300A (en) * 1992-12-07 1998-09-22 Ribozyme Pharmaceuticals, Inc. TNF-α ribozymes
US5616488A (en) * 1992-12-07 1997-04-01 Ribozyme Pharmaceuticals, Inc. IL-5 targeted ribozymes
WO1994015943A1 (en) * 1992-12-31 1994-07-21 Texas Biotechnology Corporation Antisense molecules directed against a platelet derived growth factor receptor related gene
US5639655A (en) * 1993-01-19 1997-06-17 Ribozyme Pharmaceuticals, Inc. PML-RARA targeted ribozymes
US5496731A (en) * 1993-03-25 1996-03-05 Xu; Hong-Ji Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy
US5645829A (en) * 1993-06-18 1997-07-08 Beth Israel Hospital Association Mesothelial cell gene therapy
US5739309A (en) * 1993-07-19 1998-04-14 Gen-Probe Incorporated Enhancement of oligonucleotide inhibition of protein production, cell proliferation and / or multiplication of infectious disease pathogens
ATE239787T1 (de) * 1993-07-19 2003-05-15 Gen Probe Inc Oligonukleotide mit wirkung gegen den menschlichen immunodefiziens-virus
WO1995011301A1 (en) * 1993-10-19 1995-04-27 The Regents Of The University Of Michigan P53-mediated apoptosis
US5700657A (en) * 1993-12-13 1997-12-23 Genzyme Corporation Vectors and vector systems including genes encoding tumor suppressor proteins and producer cells transformed thereby
US5834440A (en) * 1994-03-07 1998-11-10 Immusol Incorporated Ribozyme therapy for the inhibition of restenosis
WO1995024202A1 (en) * 1994-03-07 1995-09-14 Immusol, Inc. Ribozyme therapy for restenosis
WO1995024477A1 (en) * 1994-03-08 1995-09-14 City Of Hope Human papillomavirus targeted ribozymes
US6103890A (en) * 1994-05-18 2000-08-15 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids that cleave C-fos
AUPM672594A0 (en) * 1994-07-08 1994-08-04 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
WO1996015245A1 (en) * 1994-11-11 1996-05-23 Arch Development Corporation A process of inhibiting non-neoplastic pathological cell proliferation
US5869040A (en) * 1995-06-07 1999-02-09 Biogen, Inc Gene therapy methods and compositions
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
JP2000510449A (ja) 1996-04-10 2000-08-15 南カリフォルニア大学 増殖性硝子体網膜症に対する遺伝子治療
US6054467A (en) * 1996-07-05 2000-04-25 Sidney Kimmel Cancer Center Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis
WO1998001148A1 (en) 1996-07-09 1998-01-15 President And Fellows Of Harvard College Use of papillomavirus e2 protein in treating papillomavirus-infected cells and compositions containing the protein
US5958892A (en) 1996-07-30 1999-09-28 Board Of Regents, The University Of Texas System 2-methoxyestradiol-induced apoptosis in cancer cells
AU4644297A (en) * 1996-09-06 1998-03-26 Trustees Of Columbia University In The City Of New York, The Reversal of cancer phenotype by inhibiting expression of prostate tumor inducing gene
US6057156A (en) * 1997-01-31 2000-05-02 Robozyme Pharmaceuticals, Inc. Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors
EP1117768A4 (en) * 1998-08-13 2003-09-03 Johnson & Johnson Res Pty Ltd DNAZYMS AND METHOD FOR TREATING RESTENOSES
AU1219400A (en) * 1998-10-22 2000-05-08 Duke University Methods of screening for risk of proliferative disease and methods for the treatment of proliferative disease
DE60025391D1 (de) * 1999-10-26 2006-03-30 Immusol Inc Ribozym-therapie zur behandlung von proliferativen augenkranheiten
CN1564826A (zh) 2001-02-09 2005-01-12 人类基因组科学公司 人类g蛋白趋化因子受体(ccr5)hdgnr10
WO2004097020A2 (en) * 2003-04-25 2004-11-11 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase gene expression
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2004206250B8 (en) 2003-01-21 2009-09-17 Bristol-Myers Squibb Company Polynucleotide encoding a novel acyl coenzyme a, monoacylglycerol acyltransferase-3 (MGAT3), and uses thereof
WO2006128063A2 (en) * 2005-05-25 2006-11-30 Irm Llc Methods and compositions for inhibiting glioma growth
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
ES2663009T3 (es) 2010-10-29 2018-04-10 Sirna Therapeutics, Inc. Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4740463A (en) * 1984-04-13 1988-04-26 Massachusetts Institute Of Technology Methods and artificial genes for antagonizing the function of an oncogene
DE68928728T2 (de) * 1988-01-21 1998-12-10 Massachusetts Eye & Ear Infirmary, Boston, Mass. Diagnose von retinoblastoma
WO1989012687A1 (en) * 1988-06-16 1989-12-28 La Jolla Cancer Research Foundation Retinoic acid receptor
US5098890A (en) * 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
CA2006008C (en) * 1988-12-20 2000-02-15 Donald J. Kessler Method for making synthetic oligonucleotides which bind specifically to target sites on duplex dna molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
DK0520029T3 (da) * 1990-03-14 1995-10-16 Washington Res Found Fremgangsmåde og forbindelse til behandling af maligne forekomster, hvortil der er knyttet en proteinkinase
AU7152191A (en) * 1990-06-07 1991-12-31 City Of Hope Ribozyme mediated reversal of transformation by cleavage of the hras oncogene rna
NO312681B1 (no) * 1990-08-24 2002-06-17 Univ California Fremgangsmåte for fremstilling av en farmasöytisk blanding med suppresiv virkning/aktivitet
US5262321A (en) * 1991-05-31 1993-11-16 Dana-Farber Cancer Institute DNA encoding p107 tumor suppressor

Also Published As

Publication number Publication date
ATE190652T1 (de) 2000-04-15
IE20010427A1 (en) 2003-03-05
JPH05507067A (ja) 1993-10-14
DK0527804T3 (da) 2000-06-05
WO1991015580A1 (en) 1991-10-17
NO923917D0 (no) 1992-10-08
KR100304033B1 (ko) 2001-12-15
CN1057121C (zh) 2000-10-04
DE69132047D1 (de) 2000-04-20
DE69132047T2 (de) 2000-07-13
IL97774A0 (en) 1992-06-21
AU9048698A (en) 1999-01-14
CA2079903A1 (en) 1991-10-11
ZA912491B (en) 1993-02-24
PT97316A (pt) 1991-12-31
EP0527804A4 (en) 1993-07-14
AU7750191A (en) 1991-10-30
CN1056427A (zh) 1991-11-27
AU3319495A (en) 1996-03-07
PT97316B (pt) 1998-08-31
EP0960941A1 (en) 1999-12-01
KR937000652A (ko) 1993-03-15
EP0527804B1 (en) 2000-03-15
NO923917L (no) 1992-12-01
IE911115A1 (en) 1991-10-23
EP0527804A1 (en) 1993-02-24
FI924574A7 (fi) 1992-10-09
ES2143463T3 (es) 2000-05-16
GR3033695T3 (en) 2000-10-31
FI924574L (fi) 1992-10-09

Similar Documents

Publication Publication Date Title
FI924574A0 (fi) Genterapi foer cellproliferativa sjukdomar
DE3380598D1 (en) Cysteine-depleted muteins of interferon-beta, their preparation, formulations containing them, and structural genes, vectors and organisms, and their production, suitable for use in the preparation of said muteins
IL64243A (en) Hybrid human leukocyte interferon type anti-viral polypeptides,their preparation by genetic engineering methods and pharmaceutical compositions containing them
DE69434980D1 (de) Stabile bakterizide Proteine, welche die Permeabilität erhöhen und pharmazeutische Zusammensetzungen, diese enthaltend
DE3382760D1 (de) Herstellung von funktionellen menschlichen Urokinasepolypeptiden.
DE69433371D1 (de) Polypeptid, fähig zur Inhibierung der Bindung zwischen menschliches IL-6 und dessen Rezeptor
DE3853918D1 (de) Biologisch aktive bakterientötende/durchlässigkeitserhöhende proteinfragmente.
NO890259D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive etylfenoksyacetamider.
ATE294859T1 (de) Polypeptid, humanin, welches das absterben von nervenzellen hemmt
PT817851E (pt) Dna codificador do virus do papiloma humano tipo 18
NO177863C (no) Fremgangsmåte for fremstilling av rekombinant humant IFN-type I, IFN1, IFN-pseudo-2, -3, og -4, samt ekspresjonsvektorer
IL80562A0 (en) Recombinant human lysozyme,its preparation by recombinant dna technology and pharmaceutical compositions containing it
ES2081817T3 (es) Polipeptido con secuencias principales repetidas que se fijan en la celula.
ES2012940A6 (es) Un procedimiento para la preparacion de una celula de mamifero capaz de expresar interleukin-2 humana.
DE59108947D1 (de) Neues menschliches, rekombinantes interferon gamma
ATE80912T1 (de) Menschliche proteine des chinolinesterase-typs und ihre herstellung.
IE871358L (en) Interferon for carcinoma

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: CANJI, INC.

FD Application lapsed